Thursday, November 4, 2010

Keeping You in the Loop: Shingles Vaccine

Great news about a trial we participated in for a shingles vaccine called Zostavax in adults age 50-59!  Thanks first and foremost to the many hundreds of volunteers that participated in these trials with us, as well as to the sites that conducted them.  The shingles vaccine is approved for use in adults 60 and older.  The goal of this trial was to see if the vaccine prevented shingles outbreaks in a younger population than what the vaccine is currently approved for.  We received word today that, in fact, the trial showed that it reduced the incidence of shingles by 70% in the younger group of patients, so Merck has requested FDA approval of Zostavax in adults 50-59.  Stay tuned for more information about the possible approval of Zostavax in adults that are 50-59 years of age.   Click here to read more about this trial's results.

No comments :

Post a Comment

Subscribe Via Email